The poster at ADA 2022 will highlight the development of Aspect’s bioengineered pancreatic tissue therapeutic
Vancouver, BC, Canada - June 4, 2022 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present on the development of its pancreatic tissue therapeutic program at the American Diabetes Association 82nd Scientific Sessions (ADA 2022), held June 3-7, 2022 in New Orleans, LA and virtually.
“We are highly encouraged by the latest results from our pancreatic tissue therapeutic program and are proud to be sharing them at one of the leading forums for diabetes research,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “These results show that our allogeneic bioprinted tissues demonstrate long-term control of blood glucose in immune-competent diabetic animals, which represents a crucial step forward in our development of a cell-based therapy that doesn’t require chronic immune suppression.”
Poster Presentation Details:
Bioprinted Allogeneic Islet–Containing Implants Normalize Blood Glucose Control in Diabetic Rat Models without Immune Suppression
- Date/Time: Sunday, June 5, 2022 12:00-1:00 PM CT
- Session: Clinical Therapeutics/New Technology
- Poster Number: 816-P
- Location: Hall D-E
About Aspect Biosystems
Aspect Biosystems is a biotechnology company creating bioengineered tissue therapeutics to transform how we treat disease. Aspect is leveraging its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science to create a pipeline of allogeneic cell-based tissue therapeutics that replace or repair damaged organ functions. These therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at www.aspectbiosystems.com.